UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 GSK plc (the 'Company')
 
Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares
 
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') of conditional awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2023 under the GSK Share Value Plan and the subsequent sale of Ordinary Shares and ADS to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 9 February 2026.
 
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Lynn Baxter
b)
Position/status
 
President, Europe
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£0.00
 
10,050
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Lynn Baxter
b)
Position/status
 
President, Europe
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£21.9082
 
4,084
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mike Crichton
b)
Position/status
 
President, International
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  
a)
Name
 
GSK plc
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£0.00
 
10,050
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Mike Crichton
b)
Position/status
 
President, International
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£21.9082
 
3,920
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 

1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Maya Martinez-Davis
b)
Position/status
 
President, US
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADS')
 
ISIN: US37733W2044
 
b)
Nature of the transaction
The vesting of ADS awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$0.00
 
10,658
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Maya Martinez-Davis
b)
Position/status
 
President, US
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADS')
 
ISIN: US37733W2044
 
b)
Nature of the transaction
The sale of ADS to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$59.0729
 
2,789
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Nina Mojas
b)
Position/status
 
President, Global Product Strategy
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£0.00
 
23,120
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Nina Mojas
b)
Position/status
 
President, Global Product Strategy
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£21.9082
 
6,104
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
2026-02-09
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Victoria Whyte
b)
Position/status
 
SVP & Company Secretary
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£0.00
 
10,050
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Victoria Whyte
b)
Position/status
 
SVP & Company Secretary
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£21.9082
 
4,724
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Neil Falkingham
b)
Position/status
 
PCA of Lynn Baxter (President, Europe)
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£0.00
 
10,050
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Neil Falkingham
b)
Position/status
 
PCA of Lynn Baxter (President, Europe)
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£21.9082
 
4,373
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume 
Price
 
 
e)
Date of the transaction
 
2026-02-09
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
Registered in England & Wales:
No. 3888792
 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: February 11, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc